Funding fuels expansion of the country’s most established developmental therapy model. Series C round led by aMoon Fund, B Capital and Flare Capital Partners with participation from Healthworx, ...
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Our study included a broad cohort of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results